Almudena Ortiz-Garcia
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma.
Journal: Leukemia
Published: May 10, 2024
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Journal: Science translational medicine
Published: February 14, 2024
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Journal: Frontiers in immunology
Published: December 04, 2023
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Journal: Frontiers in immunology
Published: June 20, 2023
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Journal: Frontiers in immunology
Published: March 17, 2023
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
Journal: Frontiers in immunology
Published: May 26, 2022
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma.
Journal: Cancers
Published: February 28, 2021
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.
Journal: Cancers
Published: November 30, 2020
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Journal: Blood cancer journal
Published: August 05, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026